About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Myelofibrosis Symptoms may be Reduced in a Better Manner by Ruxolinitib

by Kathy Jones on December 15, 2011 at 5:50 PM
Font : A-A+

 Myelofibrosis Symptoms may be Reduced in a Better Manner by Ruxolinitib

A multicenter study has found that ruxolinitib is better than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis.

These symptoms of myelofibrosis, include pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss. The results were presented today at the annual meeting of the American Society of Hematology and Oncology in San Diego.

Advertisement

Myelofibrosis is a bone marrow disorder that disrupts the body's normal production of blood cells, resulting in extensive scarring in the bone marrow. Patients tend to be over age 50.

"For years, researchers have struggled to find effective medications to help patients struggling with symptoms of this chronic pre-leukemia condition," says lead investigator Ruben Mesa, M.D., of Mayo Clinic in Arizona. There are several thousand new myelofibrosis patients in the U.S. every year.
Advertisement

Only about 10 percent of myelofibrosis patients are eligible for a bone marrow transplant and chemotherapy often falls short, Dr. Mesa says. A handful of off-label chemotherapy drugs have been modestly helpful, he says.

A randomized, double-blind clinical trial, known as the COMFORT-1 study, showed that ruxolinitib reduced spleen size by more than 35 percent in almost all of the 154 patients studied. An enlarged spleen, caused by sequestered over-proliferating blood cells, causes discomfort and can also lead to the need for blood transfusions and further medical complications for patients.

In the study, patients treated with ruxolinitib also reported less severe symptoms than those reported by patients treated with a placebo.

A tandem randomized investigation in Europe, known as the COMFORT-2 study, showed that ruxolinitib also was more effective at reducing symptoms than the best available chemotherapies -- specifically, the off-label drugs doctors have been offering.

"The studies confirmed the drug is very effective. As a representative of a particular class of molecular inhibitors called JAK2 inhibitors, which are now being widely studied, ruxolinitib suggests this category will continue to be promising for myelofibrosis," Dr. Mesa says.Most surprising for researchers, however, was the ultimate comparison between the two clinical trials.

"When we looked at the control arms of the two studies we found that the best available chemotherapies we've been using up to this time are no more effective than a placebo," Dr. Mesa says. The comparison provided a wake-up call, he adds. "This was a unique piece of information we hadn't had in the past, and it offers further incentive and pressure to find better therapies for patients."
Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Get Involved and Stand Up for Human Rights on Human Rights Day 2022
Coronary Artery Bypass Grafting
Macronutrients Calculator for Weight Loss
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Daily Calorie Requirements Sinopril (2mg) (Lacidipine) Drug - Food Interactions Noscaphene (Noscapine) Blood Donation - Recipients Drug Interaction Checker Accident and Trauma Care Vent Forte (Theophylline) Find a Doctor Hearing Loss Calculator
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Myelofibrosis Symptoms may be Reduced in a Better Manner by Ruxolinitib Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests